Waisman Biomanufacturing is a hybrid industry-academic CDMO strategically affiliated with the University of Wisconsin-Madison. It is not a SaaS product or enterprise software platform; rather, it is a service organization that provides process development, CGMP manufacturing, quality control, and regulatory support to help novel biologics, vaccines, and therapeutic products enter early-stage clinical trials.
Its capability chain covers Process Development, GMP Manufacturing, Quality Control, and QA and Regulatory Support. Product areas include plasmid DNA, recombinant proteins, cell therapies, EV/Secretome, live biotherapeutic products, and aseptic fill-finish. The website discloses a considerable amount of equipment and method detail, such as 30-120L plasmid fermentation, 50-250L mammalian cell culture, TFF, chromatography, HPLC, qPCR, endotoxin testing, sterility testing, and bioburden testing. On the QA side, it can provide audited batch records, CMC IND Module 3 eCTD support, and authorization to cross-reference a Type V Facility Master File already submitted to FDA CBER/CDER.
The website does not provide packages, subscriptions, or standard pricing, and repeatedly directs visitors to βContact to Discuss the Proposal Process.β Its business model should therefore be understood as project-based service quotations, customized by product type, process stage, GMP batch requirements, QC scope, and the extent of regulatory support needed.
Its strengths are a complete closed-loop offering from laboratory process scale-up to clinical-grade production, QC release, and submission support, along with clearly described capabilities across several early-clinical areas such as plasmid DNA, proteins, and cell therapy. The downside is that it is not a software product: there is no free trial, API, cloud deployment, permission management, or other enterprise software functionality. Pricing, delivery timelines, and capacity scheduling are also not publicly disclosed, so procurement evaluation requires fairly in-depth commercial discussions.
It is suitable for biotech companies, university laboratories, and government/federal programs, especially teams advancing candidate vaccines, biologics, cell therapies, or plasmid DNA materials around the preclinical to Phase I/II stage. It is not suitable for organizations looking for a SaaS platform, electronic lab notebook, LIMS, or QMS software.
Access from mainland China cannot be determined from the available text, so it should be marked as unknown. Payment methods are not disclosed. If China-based teams need a local CDMO or more convenient cross-border communication, they may compare providers such as WuXi Biologics and GenScript ProBio. International alternatives include Lonza, Catalent, Thermo Fisher Scientific CDMO, and AGC Biologics.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on gmpbio.org official site.
gmpbio.org is an United States SaaS Tools provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach gmpbio.org directly.